LEADS BIOLABS-B (09887.HK) Stock Community - Hot Topic Discussions - Longbridge

Quote List Quote List

Event Tracking

Dec7

Vilimiabo Announces Clinical Trial Results of GPRC5D/CD3 Bispecific Antibody LBL-034 at ASH Annual Meeting

10:18

Dec1

Vilithibio-B's Self-Developed Candidate Drug LBL-047 Approved for Clinical Trials by NMPA

08:35

Nov12

Cinda Securities Points Out Vitalibo's LBL-024 Development Breakthrough

02:53

Nov10

Vilitebo-B Announces Progress in Phase II Clinical Trial of Opatnib for Hepatocellular Carcinoma

08:44

Nov3

Vilithibio-B's LBL-034 Research Abstract Selected for Oral Presentation at 67th ASH Annual Meeting

22:39

Cinda Securities: Vileebio's LBL-024 Antibody Poised to Become Next-Gen Immunotherapy Cornerstone Drug

05:22

Schedules & Filings

Schedules

Filings

Aug29

Earning Release(CST)

FY2025 Q2 Earning Release (HKD) Net Income -99.63 M, EPS -0.6366

Jul25

IPO(CST)

Listing Price HKD 35

Jul16

Earning Release(CST)

FY2025 Q1 Earning Release (HKD) Net Income -80.72 M, EPS -0.5157

View More

Stock List

Top Gainers

Top Decliners

Main Board

Symbol

Price

%Chg

Change

View More